Topical Minocycline Induced Bluish Black Hyperpigmentation in Acne Vulgaris Patient: The First Case Report of Topical Application
The First Case Report of Topical Application
Abstract
Minocycline induced hyperpigmentation is an aesthetically unsetting adverse drug event. Oral minocycline inducing hyperpigmentation is common course, keeping in line with this topical minocycline 4% was formulated. A moderately built woman diagnosed with acne was prescribed with topical minocycline 4% Gel and after 15 days of application she noticed dark patches on applied areas which progressed into macules. On examination, it was found that the topical minocycline has induced Type I (Bluish Black) Hyperpigmentation. To the best of clinician’s knowledge, the drug was withdrawn and observed over a period of month. Post-withdrawal for 30-days the skin started to regain its original tone. Regardless of the fact that the topical formulation has been designed to reduce the drug contact with the systemic circulation and to decrease the side-effects, will the formulation succeed in providing the effective and safe therapy in acne patients?
Keywords: Topical Minocycline 4%, Hyperpigmentation, Type I, Bluish Black Pigmentation, Acne Vulgaris
Keywords:
Topical Minocycline 4%, Hyperpigmentation, Type 1 Hyperpigmentation, Bluish Black Pigmentation, Acne VulgarisDOI
https://doi.org/10.22270/jddt.v14i4.6515References
2. Lee HJ. The biggest and popular prescribed antibiotic for acne, minocycline & doxycycline. 프로그램북 (구 초록집). 2022;74:177-9.
3. Valentín S, Morales A, Sánchez JL, Rivera A. Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol 2009;2:129-140. https://doi.org/10.2147/CCID.S4296 PMid:21436975 PMCid:PMC3047926
4. Li Y, Zhen X, Yao X, Lu J. Successful Treatment of Minocycline-Induced Facial Hyperpigmentation with a Combination of Chemical Peels and Intense Pulsed Light. Clinical, Cosmetic and Investigational Dermatology. 2023:253-6. https://doi.org/10.2147/CCID.S394754 PMid:36726812 PMCid:PMC9885878
5. Highlights of Prescribing Infomrmation AMZEEQTM. FDA. 2019 Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212379s000lbl.pdf [Accessed on 27 August 2023].
6. Fiscus V, Hankinson A, Alweis R. Minocycline-induced hyperpigmentation. J Community Hosp Intern Med Perspect 2014 Jul 31;4. https://doi.org/10.3402/jchimp.v4.24063 PMid:25147636 PMCid:PMC4120055
7. Narayanan A, Chandrashekhar L. Drug-induced pigmentation. Pigment International. 2022;9:82-92. https://doi.org/10.4103/pigmentinternational.pigmentinternational_55_21
8. Shute L, Walkty A, Embil JM. Minocycline-induced cutaneous hyperpigmentation. CMAJ 2020;192:E981. https://doi.org/10.1503/cmaj.200012 PMid:32839167 PMCid:PMC7840518
9. Wang RF, Ko D, Friedman BJ, Lim HW, Mohammad TF. Disorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders. Journal of the American Academy of Dermatology 2023;88:271-88. https://doi.org/10.1016/j.jaad.2022.01.051 PMid:35151757
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics 1981;30:239-45. https://doi.org/10.1038/clpt.1981.154 PMid:7249508
Published



How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).